Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
SHSE:688016's Return-on-Tangible-Asset is ranked better than 93.45% of 855
companies
in the Medical Devices & Instruments industry
Industry Median: 0.89
vs SHSE:688016: 16.42
Shanghai MicroPort Endovascular MedTech (Group) Co (SHSE:688016) Return-on-Tangible-Asset Explanation
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companyÂ’s earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companyÂ’s tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
Shanghai MicroPort Endovascular MedTech (Group) Co Return-on-Tangible-Asset Related Terms
Shanghai MicroPort Endovascular MedTech (Group) Co Return-on-Tangible-Asset Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shanghai MicroPort Endovascular MedTech (Group) Co Return-on-Tangible-Asset Chart
Shanghai MicroPort Endovascular MedTech (Group) Co Annual Data
SHSE:688016 vs ABT, SYK, MDT: Return-on-Tangible-Asset Comparison
For the Medical Devices subindustry, Shanghai MicroPort Endovascular MedTech (Group) Co's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shanghai MicroPort Endovascular MedTech (Group) Co Return-on-Tangible-Asset vs Medical Devices & Instruments Industry
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Mar. 2026) net income data.
What does a Return-on-Tangible-Asset of 16.94% mean?
Shanghai MicroPort Endovascular MedTech (Group) Co (SHSE:688016) has a Return-on-Tangible-Asset of 16.94% as of Mar. 2026. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Shanghai MicroPort Endovascular MedTech (Group) Co and its competitors. This is 21% below median its historical median of 21.40. Over the past decade, Shanghai MicroPort Endovascular MedTech (Group) Co's Return-on-Tangible-Asset has ranged from 14.04 to 56.38. According to the industry distribution chart, Shanghai MicroPort Endovascular MedTech (Group) Co ranks #56 out of 855 companies in the Medical Devices & Instruments industry, placing it in the top 6.5%.
Is Shanghai MicroPort Endovascular MedTech (Group) Co's Return-on-Tangible-Asset too high?
Shanghai MicroPort Endovascular MedTech (Group) Co's current Return-on-Tangible-Asset of 16.94% is 21% below median its 10-year median of 21.40. Over the past 10 years, this metric has ranged from a low of 14.04 to a high of 56.38. The Medical Devices & Instruments industry median Return-on-Tangible-Asset is 0.89. Shanghai MicroPort Endovascular MedTech (Group) Co's value of 16.94% is 1803.4% above this industry median. Based on the distribution chart, Shanghai MicroPort Endovascular MedTech (Group) Co ranks #56 out of 855 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Shanghai MicroPort Endovascular MedTech (Group) Co has a GF Score™ of 95/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Shanghai MicroPort Endovascular MedTech (Group) Co's Return-on-Tangible-Asset compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Shanghai MicroPort Endovascular MedTech (Group) Co ranks #56 out of 855 companies for Return-on-Tangible-Asset. This places Shanghai MicroPort Endovascular MedTech (Group) Co in the top 7% of its industry — outperforming the majority of peers. The industry median Return-on-Tangible-Asset is 0.89. Shanghai MicroPort Endovascular MedTech (Group) Co's value of 16.94% is 1803.4% above this benchmark. Historically, Shanghai MicroPort Endovascular MedTech (Group) Co's own Return-on-Tangible-Asset has ranged from 14.04 to 56.38 over the past decade. While the company's 10-year median is 21.40 vs. the industry median of 0.89, Shanghai MicroPort Endovascular MedTech (Group) Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Medical Devices & Instruments company?
The median Return-on-Tangible-Asset among Medical Devices & Instruments companies is 0.89, based on 855 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Asset significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Shanghai MicroPort Endovascular MedTech (Group) Co's current Return-on-Tangible-Asset of 16.94% is 1803.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Shanghai MicroPort Endovascular MedTech (Group) Co and its competitors. For the Medical Devices & Instruments industry, the median Return-on-Tangible-Asset is 0.89 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Shanghai MicroPort Endovascular MedTech (Group) Co's current Return-on-Tangible-Asset is 16.94%, which is 21% below median its own 10-year median of 21.40. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shanghai MicroPort Endovascular MedTech (Group) Co stock overvalued right now?
Based on GuruFocus' analysis, Shanghai MicroPort Endovascular MedTech (Group) Co (SHSE:688016) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥123.21, compared to a current price of ¥92.86 — trading 24.6% below its estimated fair value. The current Return-on-Tangible-Asset is 16.94%, which is 21% below median its 10-year median of 21.40 and 1803.4% above the Medical Devices & Instruments industry median of 0.89. Shanghai MicroPort Endovascular MedTech (Group) Co's overall GF Score™ is 95/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For Shanghai MicroPort Endovascular MedTech (Group) Co (SHSE:688016), the current Return-on-Tangible-Asset is 16.94% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Shanghai MicroPort Endovascular MedTech (Group) Co (SHSE:688016) Overvalued in 2026?
Based on GuruFocus' analysis, Shanghai MicroPort Endovascular MedTech (Group) Co stock appears to be undervalued.
The current stock price of Â¥92.86 is trading 24.6% below its estimated GF Value™ of Â¥123.21.
GuruFocus considers Shanghai MicroPort Endovascular MedTech (Group) Co to be Modestly Undervalued.
Key valuation signals for SHSE:688016:
Return-on-Tangible-Asset: 16.94% (21% below median its 10-year median of 21.40)
GF Value™: Â¥123.21 vs. price of Â¥92.86 (24.6% below fair value)
Industry Position: 1803.4% above the Medical Devices & Instruments median (#56 of 855)
No single metric tells the full story. See the SHSE:688016 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Shanghai Microport Endovascular Medtech Co Ltd is engaged in the Research, development, production and sales of interventional medical devices for the aorta and peripheral blood vessels.
95GF Score
Get the complete analysis for SHSE:688016
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688016 has been successfully added to your 
